– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –
– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity –
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.Chief...
Barchart Research What to Expect from PTCT Earnings PTCT Generated May 6, 2026 Current Price $66.57 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 7.20% PTC Therapeutics Reports With Votoplam...
WARREN, N.J. , May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -
WARREN, N.J. , April 28, 2026 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim...
WARREN, N.J. , April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial...
WARREN, N.J. , April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate...